NOT TRANFERABLE

TENDER NO. :- BPPI/Drugs Testing/31

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR 2015-2017

Dated: 12.10.2015

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA
(Set up under the Department of Pharmaceuticals, Govt. of India)
IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON 122016
Telephone: **0124-4303751/56**; Fax: **0124-2340370** Website: **janaushadhi.gov.in**

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)
(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)
Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003
Working Office: IDPL CORPORATE OFFICE, IDPL COMPLEX, DUNDAHERA, GURGAON (HR)

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR 2015-2017

Important Dates:	
Tender Reference Number	BPPI/Drug Testing/031 Date 12/10/2015
Date of availability of Tender documents on website	12/10/2015 (Monday)
Last date and time for receipt of Tender	02/11/2015(Monday)15.00 hrs
Date and time of Opening of Tender	02/11/2015(Monday)15.30 hrs
Place of Opening of Tender	BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon (HR)
Address For Communication	BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon (HR)-122016
Contact Person for clarification if any:	
1. Mr. K. Chopra, Director (Operation & Marketing) Phone: 0124-4040759, Mob: 9711003043 Email: kchopra.bppi@gmail.com	2. Mr. Mahadev Agarwal, Manager (Regulatory) Phone: 0124-4556756, Mob: 9873294473 Email: mahadevpharm.bppi@gmail.com

CONTENTS

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under Department of Pharmaceuticals, Govt. of India)

TENDER FOR EMPANELMENT OF DRUGS TESTING LABORATORIES FOR ANALYSIS OF DRUGS & MEDICINES FOR BPPI FOR TWO YEAR (2015-17) FROM THE DATE OF ACCEPTANCE OF TENDER

"CONFIDENTIALITY IS THE ESSENCE OF THIS TENDER"

1. Sealed tenders are invited till 02/11/2015 Monday (15.00 hours) by **General Manager (A&F) at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana)**, **(Herein referred as Tender inviting authority unless the context otherwise requires)** for empanelment of approved drug testing laboratories (under Drugs & Cosmetics Act 1940 & Rules 1945) which are GLP compliant (as per Schedule L1) and NABL accredited for drugs requiring Chemical/Physico-chemical, instrumental and microbiological testing facilities **for a period of two years** from the date of acceptance of tender by BPPI. The agreement may be extended for further period on mutually agreed terms.

The complete set of tender document can be downloaded from the BPPI website **janaushadhi.gov.in** and **pharmaceuticals.gov.in** free of cost**.**

NOTE:- LATE TENDER IS NOT ACCEPTABLE

2. Eligibility Criteria:

(a). National Accreditation Board for Testing and Calibration Laboratories (NABL) accredited analytical laboratories having approval/license under the Drugs and Cosmetics Act and Rules 1945 with minimum two years experience in the analysis of DRUGS & MEDICINES with an minimum average annual turnover of Rs. 30 Lakhs for last two years (Govt./CPSU's Laboratories, Research and Development Laboratories, Laboratories run by Co-operative body and Educational Institutions are exempted from the turnover criteria) ***however turnover for the year 2013-14 should not be less than Rs. 30 lakhs, are eligible to participate in the tender***. Agents are not eligible to participate in the tender.

(b). Drug Testing Laboratory which is also engaged in manufacturing of medicines and participate in drug procurement as well as drug testing Laboratory tender shall not be considered for testing laboratory empanelment as eligible if their product achieve L-1 rate in any drug procurement tender by BPPI.

(C). Drug Testing laboratories should have Approval/ license under Drugs & Cosmetics Act and Rules 1945 , with two years standing in the analysis of Drugs & Medicines.

(d). Drug Testing laboratories should be GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 and should hold Schedule L1 certificate.

(e). Drug Testing laboratories should not have been banned/debarred/ black listed by any State or Central Govt. Organizations or its procurement agencies on the due date of bid submission.

(f). Drug Testing laboratory and its responsible persons should not have ever been convicted under the D & C Act 1940 and Rules 1945.

(g). Drug Testing laboratory should have all necessary instruments/equipments and required mandatory facilities for testing/analysis of Drugs and Medicines as per statutory requirement for which it is participating in the tender.

(h) Attested copy of approval and GLP Certificate of Drug Testing laboratory, duly renewed up to date issued by the state licensing authority be submitted.

3. Technical bid – Cover -'A' including Earnest Money Deposit & other Documents:

The tenderer must submit the following documents in the sealed cover super scribed **Cover -'A'** (all the documents have to be sealed and copies have to be self attested and notarized in all pages).

[a]. The Earnest Money Deposit (EMD) shall be Rs.10,000/-(Rupees Ten Thousand only) paid in the form of **Demand Draft drawn** in favour of **BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA** payable at Delhi/Gurgaon, should be sent with tender form in Cover- 'A'. The EMD is refundable however it will not earn any interest. EMD in the form of cheque/ cash/ postal order/ e-payment will not be accepted.

The EMD amount of unsuccessful bidder will be refunded to them within 30 days of finalization of tender. In respect of successful bidder (empanelled bidder), the EMD amount will be adjusted towards security deposit.

[b]. Self attested and notarized photocopies of Approval/ license issued by State Licensing Authority duly renewed up to date and NABL accreditation certificate.

[c]. Documentary evidence of having analyzed DRUGS & MEDICINES for the last two years with the statement in the performa given in Annexure-I

[d]. Self attested and notarized photocopy of certificate of registration for Service Tax should be enclosed in Annexure-II.

[e]. Non conviction certificate issued by State Licensing Authority (SLA)/Competent Authority which should not be 6 months old on date of submission of bid.

[f]. Self attested and notarized document of the following should be furnished in the format given in Annexure-III

(i). List of qualified personnel employed in Drug Testing laboratory along with their qualification, experience and details of their approvals (copy of the approval).

(ii). List of sophisticated instruments (working condition) available in Drug Testing laboratory.

(iii). Facilities available in Microbiological Section in the laboratory

[g]. A declaration in the Performa given in Annexure-IV duly signed and notarized.

[h]. Details of DRUGS & MEDICINES to be analyzed to be given in Annexure-V

[i]. Documentary evidence regarding constitution of Drug Testing laboratory viz. Memorandum and Articles of Association, partnership deed etc, with details of name, address, telephone no., fax no., e-mail address of Managing Director/ Partner/ Proprietor etc.

[j]. The instruments such as power of attorney, Resolution of Board etc authorizing the tenderer, should be enclosed in the tender (in Cover-'A') duly signed by authorized signatory of the Drug Testing laboratory. Such authorized signatory of the tenderer should sign at the bottom of all the pages of the tender documents.

OTHER DOCUMENTS TO BE ENCLOSED: [self attested and notarized]

(k). Annual turnover statement certified by the auditors (C.A.) for last two years i.e., 2012-13 and 2013-14.

(l). Tenderer shall submit the checklist of documents in the enclosed performa in Annexure –VI

4. PRICE BID (COVER-'B')

(a). **Price Bid (Annexure VII)** of the tenderer duly filled in giving the rate of testing, charges for complete testing of each sample and signed on each page by authorized person with company seal, should be sent in separate sealed cover indicating name of the tenderer and superscribing "Price Bid" Cover –'B' hereafter called Cover-'B'.

(b). Cover-'B' shall contain the rates quoted by the tenderer only. It shall not contain any other document. No condition shall be indicated in the price bid. All the terms and conditions shall be indicated only in the technical bid.

(c). The tender documents and certificates must be submitted in a separate sealed cover as **Cover-'A'** and Price Bid shall be kept in separate sealed cover as **Cover-'B'**. Both **Cover-'A'** and **Cover-'B'** shall be kept in single sealed cover on which it shall be superscribed as "**TENDER FOR**

(d). The tender document should reach **General Manager, BPPI, IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana), till** 02/11/2015 **15.00 hour.**

(e). If the last date of submission is declared holiday, the tenders may be submitted on next working day upto 10.30 A.M.

(f). Tenderers should also enclose soft copy of Price Bid in CD along with Cover-'B'

5. GENERAL CONDITIONS

i. Forms in all annexure should be filled up properly. Every correction should invariably be attested by tenderer, failing which the tender will be summarily rejected.

ii. The tenderer should quote the rates for complete analysis as per the pharmacopoeial or other standards as per provisions of Drugs and Cosmetics Act 1940 for each drug and medicine not for individual test to be performed.

iii. The rates should be exclusive of taxes.

iv. The rates quoted and accepted will be binding on the tenderer for stipulated period and on no account any revision will be entertained till the completion of the contract period.

v. If in any circumstances (like breakdown of instrument or non-availability of reference standard and impurities etc.) the Drug Testing Laboratory is unable to test sample of Medicines, the same should be reported within 24 hours from time of breakdown of instrument or non-availability of reference standard of such sample by fax/ e-mail to Manager Regulatory.

vi. The tender submitted by the laboratory which has been blacklisted by the State / Central Govt. organization, shall not be considered.

vii. The laboratory will not be permitted to outsource any test from other Drug Testing laboratory.

6. ACCEPTANCE OF TENDER

i. Out of two covers submitted by each tenderer, Cover- 'A' will be opened first at **15.30 hours on 02/11/2015** in the presence of tenderers or their authorized representatives who chooses to be present. After scrutiny of the documents and information furnished in Cover-'A' and confirmation of details stated therein, a list of eligible laboratories will be shortlisted.

ii. Cover-'B' (Price Bid) of the tenderers found eligible on the basis of scrutiny of Cover-'A' will be opened subsequently and the date and time for opening of Cover-'B' will be intimated to the

shortlisted tenderers. The acceptable rates for analysis will be decided on the basis of L1 rates and will be communicated.

iii. The tenderers other than L1 tenderer will be given opportunity to match L1 rate and after due confirmation, their name/s will be included in the panel. If required, the empanelled laboratories will be inspected by team of officials of BPPI as and when need arises. In case sufficient Laboratories are not empanelled due to any reason, BPPI reserves right to float fresh tender during period of two years.

iv. The tender inviting authority, BPPI reserves the right to accept or reject any tender for any one or more of the items tendered for, without assigning any reason.

v. No tenderer will be allowed to withdraw their bid after opening of Price Bid.

7. AGREEMENT

All tenderer who are empanelled will have to execute an agreement on non-judicial stamp paper of Rs. 100/-(stamp duty to be paid by tenderer) in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA within 15 days from the date of intimation received by them from BPPI that their tenders have been accepted. The form of agreement is enclosed in tender document.

8. SECURITY DEPOSIT

The successful tenderers must pay a security deposit of Rs. **20,000/-**(Rupees Twenty Thousand only) including adjustment of EMD amount at the time of execution of agreement referred in Para 7 above by way of DD in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon.

9. COMPLETE ANALYSIS AND REPORTING CONDITION

(a). On empanelment and entrustment of the job, the Drug Testing Laboratory should furnish the test reports within,

(i). 8 days of receipt of sample in case of Tablet, Capsules, Ointment, Cream, Gel, Powder and Liquid oral preparations (all non-sterile dosage forms).
(ii). 21 days of receipt of sample in case of LVP/SVP, Inject able in vial/Ampoules and Dry Powder Injectable (all sterile dosage forms).
(iii). Within 24 hours of receipt of sample, the confirmation of receipt should be given to BPPI by fax / mail.

(iv). For any delay more than stipulated time as mentioned in para 9 (a)(i) and (ii) as the case may be, 5% of testing charges per week and the part thereof would be deducted as penalty. For consecutively delay for 4 times or more than 8 times in a year or a delay of more than 10 days occurs over the time period stipulated above, then the penalty would be 10% of testing charges per week and part thereof.

(b). All the test mentioned under IP, BP, USP and any other standard mentioned as per Second Schedule of under D& C Act 1940 and Rules 1945 as well as Schedule V should be carried out for each and every sample. The results obtained in the test should be mentioned in figures. Test reports not mentioning complete details as per IP, BP, and USP etc will be considered as "Incomplete test report" and the drugs testing laboratory will have to submit complete report for acceptance.

(c). "Complies" or "Passes" or "Within Limit" in result column of the test report will also be treated as incomplete test report, if the result has some value the actual value found on analysis is to be reported.

(d). Every test report must have some specific remarks as 'Standard Quality', or 'Not of Standard Quality.' Any ambiguity/ cutting will not be accepted.

(e). Test report should have Sr. No., Description of tests, Specifications and Results obtained including protocol of test applied.

(f). Spectra/Chromatograph/Dissolution profile, or other data sheets, wherever applicable, should be attached with the test report.

(g). In the case of non-pharmacopoeial products the method of analysis should be mentioned in the report AND PROTOCOL OF TEST APPLIED TO BE MENTIONED ON EACH REPORT,

(h). The test report should be sent to Manager (Regulatory), BPPI office as hard copy and simultaneously scanned copy should be sent by e-mail **mahadevpharm.bppi@gmail.com**.

(i). All test report should be submitted to BPPI in duplicate. In case of failure of sample, result should be communicated immediately to Manager (Regulatory), BPPI through phone/ fax/ e-mail and physical report should be sent with covering letter addressed to Manager (Regulatory) at Bureau of Pharma Public Sector Undertakings of India (BPPI), IDPL Corporate Office, IDPL Complex, Dundahera, Gurgaon-122016 (Haryana).

(j). If in any circumstances (like breakdown of instrument or non-availability of reference standard etc.) the Drug Testing Laboratory is unable to undertake sample, the same should be reported within 24 hours of receipt of such sample by fax/ e-mail to Manager Regulatory and sample should be returned to him immediately. 100% of charges as penalty will be imposed in case no prior information of breakdown of instrument or non-availability of reference standard before sending samples. Refer para (5)(v).

(k). If any sample is received in damaged condition by the laboratory, the sample should not be analyzed and should be sent back immediately to Manager (Regulatory), BPPI and due information should be given by fax/ e-mail.

(l). Manager (Regulatory), BPPI or authorized representatives have the right to inspect the laboratories of the tenderer who have submitted tenders before taking any decisions regarding empanelment. He may also inspect any laboratory which is empanelled at any time during continuance of tender and initiate action to terminate / cancel its empanelment and not to entrust any further testing job to the laboratory if any violation of tender conditions are noticed during such inspections.

10. PAYMENT PROVISIONS

i. No advance payment towards any analysis will be made to tenderer.

ii. No payment will be made for incomplete analysis or incomplete report. Refer Para 9 (b) to 9 (g)

iii.(a). Payments towards the analysis of DRUGS & MEDICINES will be made along with tax at the prevailing rate as applicable at the time of payment strictly as per rules

(b). Bills should be supported with the copy of test report. Efforts will be made to make payments within 30 days from the date of receipt of the bills by BPPI if same are found in order in all respect.

11. PENALTIES PROVISIONS

If the successful tenderer fails to execute the agreement and payment of security deposit after opening of Price Bid within the specified time or withdraws the tender after the intimation of acceptance of tender has been received by them or owing to any other reasons, the tenderer is unable to undertake the contract, the empanelment will be cancelled and security deposit shall stand forfeited to BPPI. Such tenderer will also be liable for all damages sustained by BPPI by reasons of breach of tender conditions. Such damages shall be assessed by CEO, BPPI whose decision shall be final.

12. BLACK LISTING PROCEDURE

(a). Non performance of any tenderer or empanelment conditions will disqualify a laboratory to participate in the next tender.

(b). To assess the correctness of the test results given by the empanelled Drug testing laboratory, samples would also be taken and sent randomly to Govt. laboratory/ CPSUs Laboratories/ any other NABL accredited labs which are not empanelled for testing and if any variation in the results is found, the result would be informed to empanelled laboratory. If there is any major variation in the analytical reports furnished by empanelled laboratories, (either pass or fail etc.) viz-a-viz Govt. /CPSUs Laboratory/ any other NABL accredited labs, the empanelled laboratory will be blacklisted for two years besides forfeiture of security deposit, after giving due opportunity to the concerned laboratory.

(c). If it is revealed that Drug Testing Laboratory is involved in any form of fraud and collusion with the suppliers of BPPI, the Drug Testing Laboratory will be black listed for five years. The

tenderer shall also be liable for action under criminal law and matter will be informed to relevant appropriate authorities for penal action against them.

(d). The CEO, BPPI will be at liberty to terminate the empanelment without assigning any reasons. The tenderer will not be entitled for any compensation whatsoever in respect of such termination.

Note:

- In all matters pertaining to tender, the decision of CEO, BPPI shall be final and binding.
- In event of any dispute arising out of tender, such dispute would be subject to the jurisdiction of civil court within Delhi.
- In case of dispute or difference arising between BPPI and empanelled Drug Testing Laboratory relating to any matter arising out of or connected with this tender agreement, such dispute or differences shall be settled in accordance with the Arbitration and Conciliation Act 1996. The venue of arbitration shall be Gurgaon.

13. AGREEMENT FORMAT

(Contract for Empanelment of Drugs Testing Laboratories for the Analysis of DRUGS & MEDICINES)

AGREEMENT MADE at _____ this _____ day of_____ 2015 at BPPI Gurgaon between M/s _____ having its registered office at _____ (hereafter referred to as 'The Laboratory' which term should include its successors, representatives, hires, executors, and administrators unless excluded by contract) on FIRST PART and Bureau of Pharma Public Sector Undertakings of India, set up under Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India as a Society registered under the societies registration act XXI of 1860, having its Registered Office at Core No. 06, 1st Floor, SCOPE Complex, Lodhi Road, New Delhi - 110003, through Mr. _____ S/o _____ , _____hereinafter referred to as **"BPPI"** (which expression shall mean and include its successors and assigns) of the SECOND PART.

WHEREAS the Laboratory has awarded a contract by BPPI to provide report and undertake the analytical work of the BPPI, (the list of medicines mentioned in the Schedule attached hereto Annexure-I and Annexure-II) at the rates noted therein and in the manner and under the terms and conditions hereinafter mentioned.

And whereas the Laboratory has deposited a sum of Rs 20000/- (Rupees Twenty thousand only) as Security Deposit for the due and faithful performance of this Agreement with the BPPI, which shall be forfeited in the event of the Laboratory's failure in performing its duties faithfully.

Now these presents witness that for carrying out the said Agreement in this behalf into execution, The Laboratory and the BPPI do hereby mutually convenient, declare, contract and agree each of them with the other of them in the manner following, that is to say,

(1). The term "Agreement", wherever used in this connection, shall mean and include the terms and conditions in tender floated by the BPPI for Empanelment of Drugs Testing, laboratories for the analysis of DRUGS & MEDICINES for the two years 2015-2017 the instructions to tenderer, the conditions of tender, acceptance of tender particulars hereinafter defined and those general and special conditions that may be added from time to time.

GENERAL TERMS & CONDITIONS:

(2). (a). The Agreement is for undertaking analysis of DRUGS & MEDICINES by the Laboratory to the BPPI of the samples specified in the Schedule attached hereto Annexure-I and Annexure-II at the rates noted against each therein on the terms and conditions set forth in the Agreement.

(b). This Agreement shall be deemed to have come into force with effect from _____ and it shall remain in force for a period upto date of _____ and may however be extended for a further period, on mutually agreed terms.

(c) Laboratory shall perform services with care, skill, and diligence, in accordance with the applicable professional standards currently recognized by such profession, and shall be responsible for the professional quality, technical accuracy, completeness, coordination, and timeliness of all items and services furnished under this Laboratory Agreement.

(d) Laboratory shall comply with all applicable NATIONAL, state, and local laws, ordinances, codes, and regulations in performing services. If Laboratory fails to meet applicable professional standards, Laboratory shall, without additional compensation, correct or revise any errors or deficiencies in items or services furnished under this Agreement.

(e) Laboratory shall retain, at a minimum, accreditation to ISO/IEC as per rules granted by a national accreditation body. Laboratory shall notify BPPI immediately if accreditation is in jeopardy or lost. Upon BPPI's request, Laboratory shall present BPPI with proof of its accreditation.

(f) For all requests made by BPPI pursuant to this Agreement, time is of the essence. The acceptance of a late performance, with or without objections or reservations by BPPI, shall not waive the right to claim damages for such breach nor constitute a waiver of the requirement of timely performance of any obligations remaining to be performed.

(g) In accordance with the ASTM Standard, all required tests shall be conducted to completion.

INSPECTION OF LABORATORY:

(3) In respect of the analysis medicines in the Schedule, the drug testing Laboratory shall allow inspection of the Laboratory at any time during the tender period by a team of Experts/Officials whom the BPPI may depute for the purpose. The Laboratory shall extend all facilities to the team to enable them to inspect premises, testing faculties, technical personals, reference standards/ working standards/ documentation as mandatory under D & C Act 1940 and Rules 1945, in the Laboratory.

RECOVERY OF MONEY DUE TO BPPI FROM THE LABORATORY:

(4). All expenses, damages and other money payable to the BPPI by the drug testing Laboratory under any provisions of this Agreement may be recovered from the amount due or subsequently becoming due from the BPPI to the Laboratory under this or any other Agreement. In case such amounts are insufficient to fully cover such expenses, damages or other money payable, it shall be lawful for the BPPI to recover the balance amount from the security deposit of the Laboratory and all other money held by BPPI and in case such Security Deposit is insufficient, then it shall also be lawful for the BPPI to recover the residue of the said expenses, damages and moneys, if necessary, by resorting to legal proceedings against the Laboratory.

AMOUNT OF SECURITY DEPOSIT TO BE MADE BY THE LABORATORY:

(5). The Laboratory shall deposit with the BPPI Rs. 20,000/- as security deposit by way of Demand Draft favoring BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA payable at Delhi/Gurgaon. This agreement comes into effect only after the laboratory has remitted the required amount of security deposit, not withstanding anything contained in Para 2 (b) of this agreement.

SUBMISSION OF BILLS FOR UNDERTAKING ANALYSIS:

(6). (a). No advance payment towards any analysis will be made to the Laboratory.

(b). All bills/invoices should be raised in duplicate in the name of Manager (Regulatory), BPPI. All payments shall be made by way of cheque drawn in favour of Laboratory account and Crossed Account Payee / NEFT only. The Laboratory shall furnish the details of their bank account no., name of bank and branch, IFSC code no. etc to the BPPI. (An original cancelled cheque leaf issued by their bank should be furnished).

ASSIGNMENT OF CONTRACT PROHIBITED:

(7). The Laboratory shall not, at any time, assign, sub-let or make over the present contract or the benefits thereof or any part thereof, to any person or persons whomsoever.

TERMINATION OF CONTRACT ON BREACH OF CONDITION:

(8).(a). In case the Laboratory fails or neglects or refuses to faithfully perform any of the covenants on his part herein contained or violates the condition in the tender document, it shall be lawful for BPPI to forfeit the amount deposited by the laboratory as security deposit and cancel the contract apart from black listing the laboratory for period of two years.

(b). In case of laboratory fails or refuses to observe, perform, fulfill and keep all or any other or more or any part of anyone of covenants, stipulations and provisions herein contain, it shall be lawful for BPPI on any such failure, neglect or refusal to put an end to this agreement and there upon every article clause and thing herein contained on the part of BPPI shall cease and be void and in case of any damage, loss, expense, differences in the cost or other moneys than or any time during the continuance of this agreement becoming due or owing by the laboratory to BPPI, it will be opened

for BPPI to recover from laboratory all such damages, losses, expenses, differences in cost or other moneys as aforesaid it shall be lawful for BPPI to appropriate the security deposit made by laboratory as herein before mentioned to reimburse all such damages, losses, expenses differences in cost and other moneys as BPPI have sustained, incurred or put to by reason of the laboratory having seen quality of any such failure, negligence or refusal as aforesaid or other breach in the performance of contract.

(c). If at any time during the course of contract it is found that information given by the laboratory to BPPI, either in tender or otherwise, is false, BPPI may put an end to contract / agreement wholly or in part and thereupon the provisions of cause (a) shall apply.

(9). The BPPI reserves its right to terminate without assigning any reasons therefore the contract/ agreement either wholly or in part without any notice to the laboratory. The laboratory will not be entitled for any compensation whatsoever in respect of such termination of contract by BPPI.

INDEMNIFICATION

(10) Laboratory will hold BPPI harmless and indemnify BPPI for any claim arising:

(1) from Laboratory's noncompliance with applicable governmental laws or regulations,
(2) from injury to Laboratory personnel while performing Laboratory's duties under this Agreement, and
(3) in any manner from the services to be performed under this Agreement and caused by Laboratory's acts or negligence.

NOTICES ETC., IN WRITING:

(11). All certificates or notices or orders for the time or for extra , varied or altered laboratory, which are to be the subject of extra or varied charges whether so described in the agreement or not, shall be in writing and unless in writing shall not be valid, binding or be or any effect whatsoever.

LABORATORIES NOT TO HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATED:

(12). The laboratory shall not be in any way interested in or concerned directly or indirectly with any of the officers, subordinates or servants of BPPI in trade, business or transactions nor shall the laboratory give or pay or promise to give or pay any such officer, subordinate or servant directly or indirectly any money or fee or other consideration under designation of custom or otherwise nor shall the laboratory permit any person or persons whomsoever to interfere in the management or performance thereof under power of attorney or otherwise without obtaining the consent of BPPI in writing.

BANKRUPTCY OF THE LABORATORY:

(13). In case the Laboratory at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of backrupcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the BPPI to put an end to the Agreement, and thereupon every article, clause and thing herein contained

to be operative on the part of the BPPI, shall cease and be void and the BPPI shall have all the rights and remedies given to him under the precedent clauses.

SERVING OF NOTICES TO LABORATORY:

(14). All notices or communications relating to or arising out this agreement or any of the terms thereof shall be considered duly served on or given to the laboratory if delivered to him or left at his premises, place of business or above.

(15). And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any Para herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of CEO, BPPI in the matter shall be final and binding on both parties.

(16) All disputes under this Agreement shall be resolved as follows. Within 15 days after written notification of the dispute, principals or officers of Laboratory and BPPI shall meet in an effort to resolve the dispute. If the dispute remains unresolved, the parties shall participate in a facilitated mediation pursuant to the rules of the Indian Arbitration and Conciliation Act, 1996 , Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI in accordance with the provisions of Arbitration Act, 1996.

(17). In the event of any disputes between the parties the dispute would be subject to the jurisdiction of civil courts within Delhi only.

(18) If any of the provisions of this agreement are held to be invalid or unenforceable in any respect, the remaining terms will remain effective and the agreement will be construed as if the invalid or unenforceable matters were never included in it. No waiver of any default will be a waiver of any future default. Neither party shall be liable for nonperformance caused in whole or in part by Acts of God, civil unrest and war.

In witness where the laboratory and CEO, BPPI acting for and on behalf of BPPI have set their hands the day, month and year written above.

Authorized Signature of BPPI	**Authorized Signature of Laboratory**
Name	Name & designation
Address and Seal	Address and Seal
Witnesses for BPPI	**Witnesses for Laboratory**
Signature	Signature
Name	Name
Address	Address

ANNEXURE-I

Proforma for Performance Statement

(1). Name of Laboratory:

(2). Address:

(3). Performance Statement:

Sr. No.	Category	No. of samples (complete analysis) tested during		Total no. of Samples
		2013-14	2014-15	
1	Tablets			
2	Capsules			
3	LVP / SVP			
4	Dry Powder Injectables (DPI)			
4	Liquid Orals/Syrups/Susp.			
6	Ointments/ Creams/ Gel/ Lotion			
7	Eye/Ear Drops / Nasal Drops			
8.	Vaccines & Sera			
9.	Others			

Note: Facilities for LAL test if available Yes/ NO

ANNEXURE-II

Details of Laboratory and Certificate of Registration for Service Tax

(1). Name of Laboratory

(2). Address of Head Office, if any:

(3). Address of Laboratory

(4). Name of contact person

(5). Phone No. :

Mobile No.:

(6). E-mail :

(7). Details of Approval/ License issued by Drugs Regulatory Authority*

(8). Validity of Approval/ License issued by Drugs Regulatory Authority:

(9). NABL Certificate No. along with discipline*

(10). Validity of NABL Certificate:

(11). Certificate of Registration for Service Tax: To be enclosed

(12). Any other certificates with details*

* enclose duly attested copy

ANNEXURE-III-A

Personnel in Laboratory

1) Total qualified technical personnel engaged in Chemical / Instrumental analysis:

2) Total qualified technical personnel engaged in Microbiological analysis:

3) Details of Competent (Approved) staff by State Licensing Authority

S. No.	Name	Designation	Qualifications	Approval in Chemical / Instrumental/ Microbiological Testing	Experience in relevant analysis (Years)

ANNEXURE-III-B

List of all functional Sophisticated Instruments/ Apparatus including used for testing of Insulin, vaccines & sera etc.

S. No.	Name of Instrument/ Apparatus	Total Number	Make	Date of Installation

Enclose additional paper

ANNEXURE-III-C

Facilities in Microbiological Section with AHU in Laboratory

1) List of reference cultures available: To be given
2) List of reference impurities available: To be Given
3) List of reference standard/ working references available: To be Given
4) Details of equipments (e.g. Incubators, Laminar Air Flow etc.)

S. No.	Name of Instrument/ Apparatus	Total Number	Make	Date of Installation

Enclose additional paper

ANNEXURE-IV

Declaration Form (To be attested by Notary)

I / We _(Name of Bidder)_____having our Head Office at _____ and Drug Testing Laboratory at _____ do hereby declare that I / we have carefully read all the conditions of the tender of Bureau of Pharma Public Sector Undertakings of India (BPPI), Gurgaon for empanelment of Drugs Testing Laboratories for analysis of DRUGS & MEDICINES for two year period (2015-2017) and abide by all conditions said therein.

I/We further declare that we have valid approval/ license issued by Drug Regulatory Authority bearing no. _____ and NABL Certificate bearing no. _____ in discipline _____.

Signature

Name of Authorized Person
Seal of Laboratory

Annexure – V

List of DRUGS & MEDICINES for the Analysis of Medicines for THE YEAR 2015-2017

Sl. No	Drug Code	Generic Name of the Medicines	Unit Size	Quoted By as Symbol (√) or yes
(1)	(2)	(3)	(4)	(5)
1	153	CISPLATIN INJECTION IP 10 MG	VIAL&WFI	
2	142	Insulin Injection (Human) I.P. strength 40iu/ml	10 ml Vial	
3	276	Enoxaparin Injection I.P. strength 40mg/0.4ml	0.4 ml	
4	277	Enoxaparin Injection I.P. strength 60 mg/0.6 ml	0.6 ml	
5	280	Heparin Sodium Injection I.P. strength 1000iu/ml	5 ml	
6	281	Heparin Sodium Injection I.P. strength 5000iu/ ml	5 ml	
7	362	BIPHASIC ISOPHANE INSULIN INJECTION IP 4O IU/ML (50:50)	10 ML VIAL	
8	419	HEPARIN SODIUM 50 IU + Benzyl Nicotinate 2 mg/ 1 gm Ointment/Cream	20 GM	
9	503	METHYLPREDNISOLONE SODIUM SUCCINATE INJECTION 1000 MG PER VIAL	VIAL & WFI	
10	600	Paracetamol IP…170 mg. Phenylephrine Hydrochloride IP…2.5 mg., Dextromethorphan Hydrochloride IP…5 mg., Chlorpheniramine Maleate IP…1.5 mg. in a flavoured syrupy base Suspension	60 ml.	
11	601	Disulfiram IP 500 mg Tablet	4s	
12	602	Cold & Flu Tab N/F (Nimesulide 100 mg Paracetamool 500 mg Cetirizine Hydrochloride 5 mg Phenylephrine Hydrochloride 5 mg Caffeine (Anhydrous) 25 mg Tablet	10's	
13	603	Cetirizine Dihydrochloride IP…5 mg., Phenylephrine Hydrochloride IP…10 mg., Paracetamol IP…325 mg. Tablet	10s	
14	604	Levocetrizine HCL 5mg, Phenylephrine HCL 5mg, Ambroxol HCL 30mg, Paracetamol 325mg Tablet	10's	
15	605	Etofylline BP…..200 mg., Salbutamol Sulphate IP equivalent to Salbutamol .4 mg, Bromhexine Hydrochloride IP…..8 mg. Tablet	10s	
16	606	Cyproheptadine 4 mg Tablet	10's	
17	607	Beclamethasone Dipropionate..0.025% w/, Neomycin Sxulphate..0.5% w/w (3500 Unit /G) Chlorocresol 0.1% w/w, Cream	15 gms.	
18	608	Betamethasone 0.05% w/w + Salicylic acid 3% w/w Ointment	20 Gm	
19	609	Silver Nitrate 0.20 % w/w, Chlorhexidine Gluconate Solution 0.20%, Preservative: Chlorocresol 0.12 % w/w, Cream	15 Gms Tube	
20	610	Cold Suspn.N/F (Paracetamol 125 mg+ Phenylephrine Hydrocloride IP 5mg + Cetirizine Dihydrocloride IP 2mg syrup	60ml	
21	611	Cyproheptadine, Hydrochloride(anhydrous) IP..2 mg.In a flavoured syrup	200 ml.	
22	612	Dusting Powder (Povidone 5% Powder	10 Gm Container	
23	613	Diclofenac Potassium BP 50 mg + Paracetamol 325 mg + Serratiopeptidase 10 mg Tablet	10's	

24	614	Paradichlorobenzene 2%+Benzocaine 2.7%+Chlorbutol 5%+Turpentine Oil15% Ear Drops	10ml	
25	615	Clobetasol Propionate USP…0.05 % w/w, Neomycin Sulphate IP equivalent to Neomycin…0.5 % w/w, Miconazole Nitrate IP…2.0 % ww, Zinc Sulphate IP…2.0 % w/w. cream	10 gms.	
26	616	Celecoxib 100 mg capsules	10's	
27	617	Celecoxib 200 mg capsules	10's	
28	618	Paracetamol IP 325 mg Bromhexine Hydrochloride 8mg Chlorpheniramine maleate 2mg Phenylephrine Hydrochloride 10mg Guaiphenesin 100mg Tablet	10's	
29	619	Cough Paed. Syrup Dextromethorphan Hydrobromide IP 5 mg. + Bromhexine HCl 4mg+ Phenylpropanolamine HCl 10 mg+ Menthol IP 0.75 mg / 5ml	60 ml Bottle	
30	620	BromhexineHCl+ Dextrometh orphan +Ammonium Chloride+Menthol syrup	100ml Bottle	
31	621	Iron & Zinc (Carbonyl Iron 50 mg+ Zinc Sulphate Monohydrate USP 61.8 mg equivalent to Elemental Zinc 22.5 mg + Folic Acid IP 0.5mg) Capsule	15's	
32	622	Cough lozenges Ginger / Lemon (2,4 Diclorobenzyl alcohol1.2 mg + Amylmetacresol 0.6 mg in Ginger /Lemon flavour	8's	
33	623	Cough lozenges Regular 2,4 - Diclorobenzyl Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg	8's	
34	624	Cough Expectorant Chlorpheniramine Maleate 2.5 mg + Ammonium chloride 125mg + Sodium Citrate 55mg	100ml Bottle	
35	625	Cough Tablets Bromhexine Hydrochloride 8.00 mg Phenylephrine Hydrochloride 5.00 mg	15's	
36	626	Dandruf Shampoo KETOCONAZOLE IP SHAMPOO 1% W/V	100ml Bottle	
37	627	Etophylline IP 115mg + Theophylline 35mg Tablet	10's	
38	628	Etophylline IP 231mg. + Theophylline 69mg Tablet	10's	
39	629	Inhalent Softgel Caps. (Camphor 25 mg + Clorothymol 5 mg + Eucalyptus 130 mg + Menthol 55 mg + Turpentine oil 110 mg	10's	
40	630	laxative Suspension (Liqid Paraffin 3.75ml+Milk of Magnesia 11.25ml)	170ml Bottle	
41	631	Ethamsylate B.P 500 mg.Tablet	10's	
42	632	Ethamsylate B.P 250 mg. Tablet	10's	
43	633	Anti-acne Gel Adapalene BP…0.1 % w/w, Clindamycin Phosphate USP equivalent to Clindamycin…1% w/w, Methyl Paraben IP…0.1 % w/w, Phenoxyethanol BP…0.25 % w/w	15 gms.Tube	
44	634	Clobetasol Proppionate BP…0.05 % w/w, Neomycin Sulhate IP…0.50 % w/w., Miconazole Nitrate IP…2.00 % w/w, Chlorhexidine Gluconate SolutionIP…0.20 %., Chlorocresol IP(as preservative) 0.10 % w/w Cream	20 gms.	
45	635	Clobetasol Propionate BP…0.05% w/w, Neomycin Sulphate IP …0.50% w/w.Miconazole Nitrate IP….2.00% w/w, Chlorhexidine Gluconate Solution…..0.20%, Chlorocresol IP (as preservative) 0.10% w/w cream	10 gms tube	
46	636	Ferric Ammonium Citrate 200 mg, Cyanocobalamin 7.5 mcg, Folic acid 0.5 mg, Zinc Sulphate 7 mg, Pyridoxine Hcl 1.5 mg, Sorbitol 70% Syrup	225 ml	

47	637	Aceclofenac 100 mg + Paracetamol 325 mg + Chorzoxazone 250 mg film coated tab.	10's	
48	638	Aceclofenac 100 mg Paracetamol 325 mg Serratiopeptidase 15 mg Tablet	10's	
49	639	Mucodilator Expectorant Terbutaline Sulphate 1.25 mg, Bromhexine 4 mg, Guaiphenesin 50 mg, Menthol 2.5 mg per 5 ml	100 ml	
50	640	Nimesulide 1% W/W Gel	20 Gm tube	
51	642	Triprolidine Hydrochloride 2.5mg Phenylephrine Hydrochloride 10mg Paracetamol 500 mg Tablet	10'S	
52	643	Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a flavour syrup base	60 ml Bottle	
53	644	Phenylephrine Hydrochloride 5.00mg Chlorpheniranmine Maleate 2.00mg Drops	15ml Bottle	
54	645	Nimesulide 100mg, Paracetamol 325mg, Chlorzoxazone 375mg Tablet	10's	
55	646	Diclofenac diethylamine BP 1.116% (equivalent to diclofenac sodium 1.0%, Linseed oil BP 3.0% + Methyl Salicylate IP 10.0%, Capsiacin USP 0.025%, Menthol IP 0.025%, Benzyl alcohol IP 1.0% (as preservative) In a gel base q.s.	30 Gm	
56	647	Diclofenac Di + Menthol 5%+ Oleum 3% + Methyl Salicylate Ointment	20 Gm	
57	648	Dethylamine BP…1.16 %, Linseed Oil BP…3 % w/w, Methyl Salicylate IP…10 % w/w, Menthol IP…5 % w/w, Excipients and Propellant q.s. to…100 % w/w Spray	35 gms.	
58	649	Dicyclomine 10mg + Act. Dimethicone 40mg per ml drop	10ml Bottle	
59	650	Mefenamic Acid 500mg+Paracetamol 325 mg Tablet	10's	
60	651	Paracetamol IP…125 mg., Mefanamic Acid IP…50 mg., in a flavoured syrup	60 ml.	
61	652	Dicyclomine 10mg + Mefenamic 250 mg Tablet	10's	
62	653	Syrup Vitamin D3 200 IU + Vitamin B12 2.5 mcg + Calcium Phosphate eq. to elemental Calcium 82 mg / 5 ml	225 ml	
63	654	Enyme Syrup Cardamom Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml	
64	655	Enyme Syrup Mix Fruit Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml	
65	656	Enzyme Drops Pepsin (1:3000) 5 mg + Fungal Diastase (1:1200) 33.33 mg/ml	15ML	
66	657	Hydroquinone 2.0% w/w + Tretinoin 0.025% w/w + Mometasone Furoate 0.1% w/w cream	15 gm	
67	658	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v Lotion	100 ml	
68	659	Chlorhexidine Gluconate 0.3% v/v + Cetrimide 0.6% w/v Lotion	200 ml	
69	660	Cetrimide 0.5% + Vit. E Acetate 0.1% + Glycerin Soap	75 gms.	
70	661	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion	100ml	
71	662	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion	200ML	
72	663	Junior Cough Syrup Chlorpheniramine Maleate 2 mg + Dextromethorphan Hydrobromide 10 mg + Phenylephrine HCl 5 mg / 5 ml	100 ml	

73	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	10 gm	
74	665	BCOMPLEX PLUS Each capsule contains - Thiamine mononitrate IP-10mg,Riboflavin IP -10 mg,Pyridoxine HCl IP-3mg,Vitamin B 12 IP - 5mcg,Niacimnamide IP -50mg,Calcium Pantothenate IP-12.5mg,Flolic Acid IP -1mg, Ascorbic Acid IP-150mg	10's	
75	666	Pheniramine Maleate I.P. 22.75mg,Methyl Paraben(as preservative) I.P. 0.135% w/v, Propyl Paraben(as preservative) I.P. 0.015% w/v, Water for injection I.P. q.s.	2ml	
76	667	Paracetamol I.P. 125 mg:+ Promethazine HCl I.P. 5 mg drop	15ml	
77	668	Multivitamin Drops : Vitamin A(as Palmitate)IP 2500 IU, Vitamin E Acetate IP 2.5 IU,Vitamin D3 IP 200 IU,Ascorbic Acid IP 40mgThiamine Hydrochloride IP 1mg,Riboflavine Sodium Phosphate IP 1.5mg,Niacinamide IP 10mg,D-Panthenol IP 3mg,D-Botin BP 50mcg ,Lysine	15ml	
78	669	Cefuroxime 125mg(asCefuroxime Axetil USP) Syrup	30ml	
79	670	Diacerein 50 mg +Methylsulphonylmethane 250 mg + Glucosamine sulphate 750 mg tab.	10's	
80	671	Diacerein 50 mg + Glucosamine Sulphate 500 mg Tablet	10's	
81	672	Mometasone Furoate 0.1 % w/w cream	15gm	
82	673	Biotin 10 mg Tablet	10's	
83	674	Sitaglptin 100 mg Tablet	10's	
84	675	Sitaglptin 50 mg Tablet	10's	
85	676	Trimcelone Acetonide 0.1 % Mouth Ulcer gel	10gm	
86	677	Flupentixol 0.5 mg Tablet.	10's	
87	678	levodopa & Carbidopa tab	10's	
88	679	Nalidixic Acid 500 mg Tablet	10's	
89	680	Finaestride 5 mg Tablet.	10's	
90	681	Phenazopyridine Hcl 100mg tab	10's	
91	682	Rabeprazole 20mg + Domperidone 10mg Tablet	10's	
92	683	Rabeprazole Sodium ip 20mg + Itopiride HCL 150mg Tablet	10's	
93	685	Pantoprazole 40mg + Itopride 150mg S.R. Tablet	10's	
94	686	Magaldrate 400 mg + Simethiocone 20 mg Syrup	170 ml	
95	687	Lactulose 10 gm/ 15 ml Suspension	200 ml	
96	688	Nitroglycerine Injection 5mg/ ml	10 ml Vial	
97	689	Clotrimazole 100 mgVaginal Tab	10's	
98	690	Timolol Maeleate 0.5 % Eye Drops	5 ml Vial	
99	691	Ofloxacin Eye Drops	5 ml Vial	
100	692	Olopattadine Eye Drops	10 ml Vial	
101	693	Tropicamide Eye Drops	5 ml Vial	
102	694	Tobramycin Eye Drops	10 ml Vial	
103	695	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg Phenulmercuiric intrate IP Ear/Eye Drop	5 ml	
104	696	Polymyxin B sulphate BP 5000 iu , Chloramphenicol IP 4mg ,Dexamethasone sodium phosphate IP 1 mg Phenulmercuiric intrate IP Ear/Eye Drop	5 ml	

105	697	Sulfacetamide eye drop 10 %	10 ml	
106	698	Sulfacetamide eye drop 20 %	20 ml	
107	699	Acyclovir Eye Ointment	5gm	
108	700	Ketamine Hydrochloride 10 mg/ml Injection	20ml Vial	
109	701	Pilocar 2 % eye drop	10 ml Vial	
110	702	Haloperidol 0.5 mg Tablet.	10's	
111	703	Nimsulide 100 mg + Serratiopeptidae 15 mg Tablet/Cap	10's	
112	704	Cephalexin 125mg/5ml dry syrup	30ml	
113	705	Levofloxacin 500 mg INFUSION / IV	100ml	
114	706	Cefpodoxime proxetil 50 mg DS dry syrup	30ml	
115	707	Piroxicam 10 mg tablets	10's	
116	708	Piroxicam 20 mg b tablets	10's	
117	709	Piroxicam 20 mg with bezyl alcohol injection	1ml	
118	710	Piroxicam 40 mg with bezyl alcohol injection	2ml	
119	711	Ofloxacin 50mg+Ornidazole125mg+Simethicone 10 mg Syrup	60ml	
120	712	Paracetamol DS syrup /250 mg	60ml	
121	713	Glibenclamide 5mg + MetforminHcl 500 mg Tablet	10's	
122	714	Ofloxacin 200mg+Ornidazole500mg infusion	100 ml	
123	715	Glycerin IP 98%w/w Syrupy Liquid	50 gm	
124	716	Urea IP 1 % + Salicylic Acid IP 1% w/w Zinc Sulphate 0.1 % w/w cream/onit/gel	10 gm	
125	717	Etodolac tablets 300 USP mg	10's	
126	718	Escitalopram 10mg with Clonazepam 0.5mg Tablet	10's	
127	720	Ringer Lactate	500ml IV fluid plastic container using FFS technology	
128	721	Water for Injection amp polypack	2ml	
129	722	Water for Injection amp polypack	5ml	
130	723	Water for Injection amp polypack	10ml	
131	724	Whey Peptide based Enteral nutrition Per 100gm Energy 464 Kcal Protin 18.5gm Fat 17 gm MUFA 1.19Gm PUFA 2.58, Carbs 59.40gm Vit A / D/ E/K/C/B1/ B2/NIACIN/B6/Folic Acid/ Pantothenic Acid / B12/ Biotin/ Minerals and Choline Taurine & Carnitine	200 gm Tin	
132	725	Dextrose 5 %	500ml IV fluid plastic container using FFS technology	
133	726	Dextrose 10 %	500ml IV fluid plastic container using FFS technology	
134	728	Dextrose with Saline 5% + 0.9%	500ml IV fluid plastic container using FFS technology	
135	732	Normal Saline (NS) 0.9% w/v	500ml IV fluid plastic container using FFS technology	

Annexure – VI
Ref. Clause no. 2 (e), 5. vi

Declaration

I ……Managing Director/Partner/Proprietor of M/s …….. having its registered office at …… …… do hereby declared that our company have not black listed/ debarred / deregistered/ either by any state Government or central Government Organization or its drug procurement agencies. We are eligible to participate in tender no……

M/s …….

Company Seal

To be attested by Notary

Annexure – VII

CHECK LIST

S. No.	Particulars	Page No.	Yes	No
1.	Annexure VI - Checklist			
2	EMD in the form of DD shall be kept in an envelope.			
3	Self attested and notorised Photo copy of licence for Drug Testing Laboratory renewed upto date.			
4	Recognition Certificate issued by NABL & its renewal			
5	Annual Turn over for the last two years certified by the auditors. i.e. 2013-2014 & 2014-2015 certified by the auditors.			
6	*GLP compliant under the provisions of Drugs & Cosmetics Act 1940 and Rules 1945 (Schedule L1 certificate.*			
7	Certificate for analysis issued by other recognized agencies			
8	Non conviction certificate as per pera 3(e)			
9	Annexure – I Proforma for performance statement			
10	Annexure – II Details of Laboratory and Certificate of Registration for service tax			
11	Annexure – III (A) Personnel in Laboratory.			
12	Annexure – III (B) List of Sophisticated instruments.			
13	Annexure – III (C) Facilities in Microbiological section			
14	1) List of reference cultures available:			
15	2) List of reference impurities available:			
16	3) List of reference standard/ working references available			
17	Annexure – IV Declaration form duly signed & notarized.			
18	Annexure – V List of DRUGS & MEDICINES			
19	Annexure – VI Declaration as pera 2(e)			
20	Documentary evidence, for the constitution of the company / laboratory ie., Memorandum and articles of Association or partnership etc.,			
21	The instruments such as power of attorney, resolution of board etc.,			
22	The tender document signed by the tenderer in all pages with official seal			
23	Documentary evidence of having analyzed drugs for the test for the last two years			
24	Whether lab engaged in mfg activities (If yes, give details)			
25	Cover B: Annexure – VII (Price Bid) Hard and softcopy in a separate cover			

Annexure – VIII

Price Bid

S. No.	Drug Code	Name of Medicine	Unit Size	Rate excluding Tax	Tax applicable in %	Total including Taxes	Remarks
1							
2							
3							
4							
5							
6							
7							

Enclose Soft Copy of Price Bid (in Excel Sheet) in CD also.